A Two One-Sided Parametric Tolerance Interval Test for Control of Delivered Dose Uniformity. Part 1—Characterization of FDA Proposed Test

FDA/CDER (2008) Draft guidance for industry “Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and controls documentation”, October 1998. http://www.fda.gov/cder/guidance/2180dft.pdf . Accessed September 11, 2008.

FDA/CDER (2008) Guidance for industry “Nasal spray and inhalation solution, suspension, and spray drug products chemistry, manufacturing, and controls documentation”. Draft: May 1999. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3609b1k.pdf . Accessed September 11, 2008. Final: July 2002. http://www.fda.gov/cder/guidance/4234fnl.pdf . Accessed September 11, 2008.

Murphy JR, Griffiths KL. Zero-tolerance criteria do not assure product quality. Pharm Tech 2006;30(1):52–60. http://www.pharmtech.com/pharmtech/content/printContentPopup.jsp?id=283486 . Accessed September 11, 2008.

M.M. Nasr. Parametric tolerance interval test for delivered dose uniformity (DDU). Presentation to Advisory Committee for Pharmaceutical Science on 25 October 2005. http://www.fda.gov./ohrms/dockets/ac/05/slides/2005-4187S1_13_Nasr.ppt . Accessed September 11, 2008.

R. Lostritto (2005) Advisory Committee for Pharmaceutical Science Meeting (in transcripts), 25 October 2005, p. 361. http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4187T1.pdf . Accessed September 11, 2008.

Montgomery DC. Introduction to statistical quality control. 5th ed. New York, NY: Wiley; 2004.

Lieberman GJ, Resnikoff GJ. Sampling plans for inspection by variables (Corr: p1333). J Am Stat Assoc. 1955;50:457–516.

USP <905>Uniformity of dosage units. The sixth interim revision announcement. Pharm Forum. (2006);32(6):1649–1659 (1st supplement to USP 30–NF 25).

USP. Explanatory note “USP-NF harmonized chapter <905>uniformity of dosage units.” http://www.usp.org/USPNF/notices/generalChapter905.html . Accessed September 11, 2008.

IPAC-RS. A parametric tolerance interval test for improved control of delivered dose uniformity of orally inhaled and nasal drug products; 2001. http://ipacrs.com/PDFs/IPAC-RS_DDU_Proposal.PDF . Accessed September 11, 2008.

Flann B. Comparison of criteria for content uniformity. J Pharm Sci. 1974;63(2):183–99.

Hauck WW, Shaikh R. Modified two-sided normal tolerance intervals for batch acceptance of dose uniformity. Pharm Stat. 2004;3(2):89–97. doi: 10.1002/pst.103 .

Hauck WW, Shaikh R. Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content. J Biopharm Stat. 2002;11(4):335–46.

Foust L, Diener M, Gorko MA, Hofer J, Larner G, LeBlond D, et al. Overcoming disincentives to process understanding in the pharmaceutical CMC environment. Pharm Technol. 2007;31(9):106–15.

Wilks SS. Determination of sample sizes for setting tolerance limits. Ann Math Stat. 1941;12:91–6.

Wald A, Wolfowitz J. Tolerance limits for a normal distribution. Ann Math Stat. 1946;17(2):208–215.

Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. New York: Wiley; 1991.

Wolfinger RD. Tolerance intervals for variance components models using bayesian simulation. J Qual Technol. 1998;30(1):18–32.

Liao CT, Lin TY, Iyer HK. One- and two-sided tolerance intervals for general balanced mixed models and unbalanced one-way random models. Technometrics. 2005;47:323–35.

Tsong Y, Shen M. Parametric two-stage sequential quality assurance test of dose content uniformity. J Biopharm Stat. 2007;17(1):143–57. doi: 10.1080/10543400601001527 .

Tsong Y, Shen M, Lostritto RT, Poochikian GK. Parametric two-tier sequential quality assurance test of delivery dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. J Biopharm Stat. 2008;18(5):976–84. doi: 10.1080/10543400802287222 .

Odeh RE, Owen DB. Tables for normal tolerance limits, sampling plans, and screening. New York: Marcel Dekker; 1980.

Casella G, Berger RL. Statistical inference. 2nd ed. Belmont, CA: Duxbury; 2001.

Li Z, DeMets DL. On the bias of estimation of a Brownian motion drift following group sequential tests. Stat Sin. 1999;9:923–37.

Lan KKG. DeMets. DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–63.

Hauck W, Shaikh R. Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content. J Biopharm Stat. 2001;11:335–46.

The R foundation for statistical computing. R version 2.6.1 (2007-11-26). ISBN 3-900051-07-0.